MedTrace Logo

A Therapeutic Exploratory Clinical Study to Evaluate the Antihypertensive Efficacy of Fimasartan (BR-A-657•K) During 24 Hours in Patients With Mild to Moderate Essential Hypertension

NCT00922441 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 92

Last updated 2018-03-15

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the antihypertensive efficacy and safety of Fimasartan (BR-A-657•K) during 24 hours by dose in patients with mild to moderate essential hypertension.

Conditions

  • Essential Hypertension

Interventions

DRUG

Fimasartan 60 mg group

Fimasartan 60 mg

DRUG

Fimasartan 120 mg group

Fimasartan 120 mg

DRUG

Reference (Valsartan 80 mg) group

Reference (Valsartan 80 mg)

Sponsors & Collaborators

  • Seoul National University Hospital

    collaborator OTHER

  • Kyungpook National University Hospital

    collaborator OTHER

  • Catholic Medical Center

    collaborator OTHER

  • Inje University

    collaborator OTHER

  • Chonnam National University Hospital

    collaborator OTHER

  • Boryung Pharmaceutical Co., Ltd

    lead INDUSTRY

Principal Investigators

  • Byung-He Oh, Professor · Seoul National University Hospital

  • Dong-Soo Kim, Professor · Inje University

  • Sung Chul Chae, Professor · Kyungpook National University Hospital

  • Gi-Sik Kim, professor · Daegu Catholic University Medical Center

  • Myung-Ho Jung, Professor · Connam National University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-12-31
Primary Completion
2009-08-31
Completion
2009-08-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00922441 on ClinicalTrials.gov